This program project is intended to serve as a combination of the applicant and his team's basic and clinical research in the use of radiolabeled antibodies for cancer therapy (radioimmunotherapy, or RAIT), supported by a NIH Outstanding Investigator Grant for two 7-year periods. The current grant will include 1 laboratory and 3 clinical research projects, as well as core laboratories addressing the common theme of developing and investigating these biological imaging and therapy agents in 3 cancer types of an endocrine nature; namely, mammary, ovary, and medullary thyroid cancers. Each cancer type will be investigated in terms of better therapy methods, the latter in combinations with chemotherapeutics of current clinical interest. The overall long-term objectives are to define the role of radioimmunotherapy in a multimodal treatment program. Specifically, the P01 will comprise: Project 1: Rational Design of Chemo- and Radioantibody Therapy (evaluate the role of multimodality, chemotherapy and RAIT, the effects on molecular markers, especially in isolated human tumor cells from patient blood samples having drug and apoptotic markers); Project 2: Radioimmunotherapy of Stage IV Breast Cancer (evaluate three Phase I trials that combine 90Y-hMN014 anti-CEA with conventional chemotherapy in the treatment of Stge IV breast cancer and assess 2 new murine antibodies against MUC-1 and EGP-1 for therapy applications); Project 3: Radioimmunotherapy of Epithelial Ovarian Cancer (evaluate the role of RAIT in combination with chemotherapy in the treatment of ovarian cancer patients who have failed standard therapy, including marrow grafting, for advanced disease, as well as evaluate antibodies to MUC-1 and EGP-1); Project 4: Radioimmunotherapy of Medullary Thyroid Cancer (evaluate the role of RAIT alone and in combination with chemotherapy in the treatment of this orphan cancer type in Phase I/II trials); Core Laboratories/Units; A. Antibody Production, QC, and Reengineering; B. Radiolabeling (Clinical and Experimental); C. Animal Experimentation; D. Histology Laboratory; E. Dosimetry, and F. Administration, Project Management, Regulatory and Statistical Units.
|Sharkey, Robert M; Hajjar, George; Yeldell, Dion et al. (2005) A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer. J Nucl Med 46:620-33|
|Blumenthal, Rosalyn D; Leone, Evelyn; Goldenberg, David M et al. (2004) An in vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: effects of p53 expression. Int J Cancer 108:293-300|
|Blumenthal, R D; Leone, E; Goldenberg, D M (2003) Tumor-specific dose scheduling of bimodal radioimmunotherapy and chemotherapy. Anticancer Res 23:4613-9|
|Goldenberg, David M (2003) Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immunother 52:281-96|
|Stein, Rhona; Chen, Susan; Reed, Linda et al. (2002) Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma: effectiveness of dacarbazine. Cancer 94:51-61|
|Goldenberg, David M (2002) Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 43:693-713|
|Blumenthal, R D; Waskewich, C; Goldenberg, D M et al. (2001) Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, celecoxib, in athymic mice bearing human breast cancer xenografts. Clin Cancer Res 7:3178-85|